Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5.88% and free cash flow fell 7.00%, each against the same quarter a year earlier.
Follow DSGN
Design Therapeutics, Inc. (DSGN) EV/Sales
As of 16 October 2026, Design Therapeutics, Inc. (DSGN) trades at a EV/Sales of 1,934×. Over the past ten years it has ranged from −834× (August 2023) to 4,709× (August 2022); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 2,218× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 2,218× | 0.00% |
| Sep 2020 | 2,218× | 0.00% |
| Jun 2020 | 2,218× | 0.00% |
| Mar 2020 | 2,218× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AURA Aura Biosciences, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 1.2× |
| MDXG MiMedx Group, Inc compare | 1.5× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| AVTX Avalo Therapeutics, Inc. compare | 82.3× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. | 1,934× |
| CADL Candel Therapeutics, Inc. compare | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)